LEO Pharma provides update on the development program for izuforant
- The Phase 2a/b international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe AD did not meet the primary endpoint.
- As a result, LEO Pharma ends the program for izuforant and terminates the license agreement with JW Pharmaceutical.
- LEO Pharma remains committed to delivering value for patients living with atopic dermatitis and other skin diseases.
BALLERUP, Denmark, October 20, 2023 – LEO Pharma today announced the initial headline conclusions from the recently completed Ph2a/b study of izuforant (LEO 152020) in atopic dermatitis (LP0190-1488).
Izuforant – which LEO Pharma has in-licensed in a global agreement with JW Pharmaceutical – was a novel atopic dermatitis drug candidate intended for oral treatment of atopic dermatitis. Izuforant was expected to maximize efficacy by dual action of anti-pruritus (anti-itch) and anti-inflammation and minimize adverse events by high selectivity on the target.
The study – a phase 2 randomized, triple-blind, placebo-controlled, parallel-group, international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe atopic dermatitis did not meet the primary endpoint; i.e. the trial did not demonstrate a statistically significant difference in the mean change from baseline in EASI total score at end of treatment between active treatment arms and placebo.
No new safety issues or concerns were identified.
"At LEO Pharma, we are committed to advancing the standard of care for people living with skin diseases. This also means investing in trials to explore potential new treatments to accommodate the high unmet need these people face every day. But unfortunately, as is the case for all pharmaceutical research, not all trials show the results we hope for," says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma. "While we are disappointed with the outcome for izuforant, which represented a potential new kind of treatment for atopic dermatitis – LEO Pharma remains fully committed to innovative research in atopic dermatitis as we strive to make a difference for people living with skin diseases and their families."
As a result of the study outcome, LEO Pharma has decided to terminate the program and end the licensing agreement with JW Pharmaceutical, who will regain all rights to izuforant
Although this study failed to meet its primary endpoints, the partnership with JW Pharmaceutical is a strong example of LEO Pharma’s commitment to delivering innovation in medical dermatology and reflects LEO Pharma’s research model, which aims at driving the early-stage pipeline through externally sourced innovation, that was announced in early 2023.
--ENDS--
About Izuforant (JW1601)
Izuforant is an orally available histamine H4 receptor inverse agonist with anti-pruritic and anti-inflammatory dual effect. It shows anti-chemotactic activity in eosinophil shape change and therapeutic effect in spontaneous NC/Nga AD model. Izuforant was out-licensed from JW Pharmaceutical to LEO Pharma in 2018.
Kontakter
Henrik Heskjær
Tlf:+45 3140 6180hdtdk@leo-pharma.comJes Broe Frederiksen
Tlf:+45 5360 5948jebfe@leo-pharma.comAbout
About JW Pharmaceutical Corporation
JW Pharmaceutical Corporation has been leading Korean medicine and medical supplies market over its 70 years of history. The company focuses on the field of research and development of anti-cancer drug and etc.; manufacture and sales of hospital fluid, antibiotic and other ethical pharmaceuticals.
JW Pharmaceutical Corporation was founded in 1945 and is listed on the Korea Exchange Market under the symbol "001060".
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,400 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris17.9.2025 16:00:00 CEST | Pressemeddelelse
Results presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1
LEO Pharma Takes Centre Stage With its Largest-Ever Scientific Programme at EADV 202515.9.2025 15:00:00 CEST | Pressemeddelelse
For the second year in a row, LEO Pharma delivers its largest and most ambitious scientific programme ever at the 2025 European Academy of Dermatology and Venereology (EADV), setting a new standard by presenting an unprecedented volume of scientific content for the company, with 5 late-breaking presentations and 24 regular abstracts.1-29 LEO Pharma’s scientific programme at EADV 2025 spans multiple dermatological indications, mirroring the company’s strong commitment to addressing both the most prevalent chronic skin diseases and hard-to-treat conditions.1-29 Highlights from EADV 2025 includes exciting phase 3 data in biologic injectables as well as foam and cream formulations, illustrating the breadth of therapeutic approaches represented in LEO Pharma’s medical dermatology portfolio.1-29
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth18.8.2025 12:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 18 August, 2025 - In H1 2025, LEO Pharma delivered robust growth and significantly improved profitability, enabling an increase to the financial outlook for sales growth and adjusted EBITDA margin in 2025 towards the upper-end of previously communicated expectations. In July, the FDA approval of Anzupgo® and partnership with Boehringer Ingelheim for SPEVIGO®, marked major strategic milestones demonstrating LEO Pharma’s commitment to advancing innovation in dermatology. Highlights LEO Pharma’s revenue increased by 6% year-on-year to DKK 6,789 million, and by 7% at constant exchange rates (CER) entirely driven by organic growth. The revenue growth was led by North America (+28% at CER), with Europe (+1% at CER) and Rest of World (+4% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 8% (CER) year-on-year, driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 51% (CER). Sales
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.23.7.2025 22:30:00 CEST | Pressemeddelelse
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs.
Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)14.7.2025 13:00:00 CEST | Pressemeddelelse
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum